Screening and Treatment of Latent Tuberculosis Among Patients Receiving Biologic Agents

Tran, Nhu Quynh; Garcia-Rosell, Melinda; Pattanaik, Debendra; Raza, Syed Hasan; Carbone, Laura D

doi:10.1097/rhu.0000000000000466

Cited by 6 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 50 Nevertheless, even in low TB prevalence countries, the majority of rheumatologists are still employing such retesting strategies. 52 In a recent study in a low prevalence country such as Greece, we found that conversion of screening assays (TST, IGRA) during long-term bDMARD therapy was common and in most cases a transient event. 53 Similarly, high conversion rates of IGRAs have been reported in health care workers during routine annual re-screenings and thus, the Centre for Disease Control (CDC) does not recommend them universally anymore, except for those at increased TB risk.…”

Section: Opportunistic Infectionsmentioning

confidence: 91%

Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies

Thomas

Vassilopoulos

2020

MJR

View full text Add to dashboard Cite

The third decade of the 21 st century marks the beginning of a new era in the treatment of rheumatoid arthritis (RA). Recently, after the introduction in clinical practice of different biologics in the first decade, three different oral synthetic targeted agents (JAK inhibitors) have been licensed for the treatment of RA, in patients who had failed or are intolerant to disease modifying anti-rheumatic drugs (DMARDs). Despite the significant progress that these agents bring to the care of RA patients, the risk of infections is still present and clear, given that their risk for serious infections is at least comparable with that of biologic DMARDs, whereas the incidence of herpes zoster is higher than that of bDMARDs. Here, we review the most recent data regarding the risk for serious and opportunistic infections in RA patients treated with biologics or JAK inhibitors, as well the up-to-date approach for managing and preventing such infections in RA patients.

show abstract

Section: Opportunistic Infectionsmentioning

confidence: 91%

Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies

Thomas

Vassilopoulos

2020

MJR

View full text Add to dashboard Cite

show abstract

“…They also differed on the frequency of LTB screening after initiating biologic therapy and the time of initiation of biologic treatment after starting LTBI therapy. Moreover, there is no consensus on the duration of LTBI therapy . The British Thoracic Society recommends collecting the details of TB risk factors and performing a CXR.…”

Section: Introductionmentioning

confidence: 99%

Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real‐world clinical experience from India

Shobha

Chandrashekara²,

Rao

et al. 2018

Int J of Rheum Dis

View full text Add to dashboard Cite

show abstract

“…Most of the studies were rated to have a low risk of bias ( n = 35) 10 , 17–27 , 29 , 31 , 33–35 , 38 , 39 , 41–44 , 46 , 47 , 49–54 , 56 , 60–62 , and 12 studies had a moderate level of risk of bias 28 , 30 , 32 , 36 , 37 , 40 , 45 , 48 , 55 , 57–59 ( Supplementary Appendix 7 ). The risk of bias primarily arose from a lack of reporting on the sampling frame ( n = 28) 10 , 17 , 28–30 , 32–34 , 37 , 38 , 40 , 41 , 43–48 , 50 , 52–55 , 57–59 , 61 , 62 and the sampling method where convenience sampling or voluntary sample was used ( n = 20). 17 , 21 , 22 , 27 , 29–31 , 33 , 36 , 38 , 42–44 , 46 , 47 , 49 , 50 , 52 , 56 , 58 Hence, there was uncertainty on whether the true close representation of the target population was established.…”

Section: Resultsmentioning

confidence: 99%

“…Moreover, half of the studies ( n = 23) did not use pilot-tested and validated study instruments for data collection. 20 , 21 , 23 , 25 , 26 , 30 , 32–38 , 41 , 47–49 , 52 , 55 , 57 , 61 , 62 This could potentially affect the reliability, consistency and accuracy of data collected.…”

Section: Resultsmentioning

confidence: 99%

How can we improve latent tuberculosis infection management using behaviour change wheel: a systematic review

Wong

Lee

2023

Journal of Public Health

View full text Add to dashboard Cite

Background To ensure the effective delivery of latent tuberculosis infection (LTBI) care, it is vital to overcome potential challenges in LTBI management. This systematic review aims to identify the barriers and interventions to improve LTBI management using the Capability, Opportunity, and Motivation-Behaviour (COM-B) model and Behaviour Change Wheel (BCW). Methods A systematic literature search was performed on five electronic databases from database inception to 3 November 2021. A two-step technique was used in the data synthesis process: (i) the barriers of LTBI management were identified using the COM-B model, followed by (ii) mapping of intervention functions from BCW to address the identified barriers. Results Forty-seven eligible articles were included in this review. The findings highlighted the need for a multifaceted approach in tackling the barriers in LTBI management across the public, provider and system levels. The barriers were summarized into suboptimal knowledge and misperception of LTBI, as well as stigma and psychosocial burden, which could be overcome with a combination of intervention functions, targeting education, environment restructuring, persuasion, modelling, training, incentivization and enablement. Conclusions The remedial strategies using BCW to facilitate policy reforms in LTBI management could serve as a value-added initiative in the global tuberculosis control and prevention program.

show abstract

Screening and Treatment of Latent Tuberculosis Among Patients Receiving Biologic Agents

Cited by 6 publications

References 14 publications

Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies

Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies

Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real‐world clinical experience from India

How can we improve latent tuberculosis infection management using behaviour change wheel: a systematic review

Contact Info

Product

Resources

About